Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
| ▸ | ACHE | P22303 | 2/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MC4R | P32245 | 1/20 | 0.49 |
| ▸ | MLNR | O43193 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | XIAP | P98170 | 1/20 | 0.46 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.46 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1307820 | 1.00 | SIGMAR1 (0.58) | SIGMAR1ACHELTA4HCYP1A2CYP3A4 | |
| SCHEMBL1826258 | 1.00 | SIGMAR1 (0.58) | SIGMAR1ACHELTA4HCYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL18788467 | 0.98 | SIGMAR1 (0.56) | SIGMAR1ACHELTA4HCYP1A2CYP3A4 | |
| Dimethylamine SCHEMBL6787869 | 0.95 | LTA4H (0.53) | SIGMAR1ACHELTA4HCYP1A2CYP3A4 | |
| SCHEMBL12469761 | 0.90 | CYP2D6 (0.54) | SIGMAR1ACHELTA4HCYP1A2CYP3A4 | |
| SCHEMBL17763473 | 0.85 | ACHE (0.67) | SIGMAR1ACHEALDH1A1MC4RLMNA | |
| SCHEMBL17830169 | 0.85 | ACHE (0.67) | SIGMAR1ACHEALDH1A1MC4RLMNA | |
| SCHEMBL13330940 | 0.85 | CXCR4 (0.53) | ACHECYP3A4ALDH1A1MLNRLMNA | |
| SCHEMBL3158803 | 0.85 | MLNR (0.49) | SIGMAR1CYP3A4ALDH1A1MLNRXIAP | |
| SCHEMBL17495605 | 0.85 | ACHE (0.67) | SIGMAR1ACHEALDH1A1MC4RLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067625-A1 | SMALL-MOLECULE MODULATORS OF THE ORPHAN NUCLEAR RECEPTOR TLX | BAYLOR COLLEGE OF MEDICINE (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2022140643-A1 | SMALL-MOLECULE MODULATORS OF THE ORPHAN NUCLEAR RECEPTOR TLX | BAYLOR COLLEGE OF MEDICINE (US) | 2022-06-30 | — | — | WO | disclosed |
| EP-1805158-B1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS INC (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
| EP-2566859-B1 | PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SK CHEMICALS CO LTD (KR) | 2016-12-21 | — | — | EP | disclosed |
| US-9096571-B2 | Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same | SK CHEMICALS CO., LTD. (KR) | 2015-08-04 | — | — | US | disclosed |
| CN-103025721-B | Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same | SK CHEMICALS CO LTD | 2015-06-17 | — | — | CN | disclosed |
| US-20130210811-A1 | PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME | SK CHEMICALS CO., LTD. (KR) | 2013-08-15 | — | — | US | disclosed |
| CN-103025721-A | Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same | SK CHEMICALS CO LTD | 2013-04-03 | — | — | CN | disclosed |
| US-8404708-B2 | Dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| EP-1368340-B1 | PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | LILLY CO ELI (US) | 2005-08-10 | — | — | EP | disclosed |
| WO-2005056015-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| CN-1629146-A | Process for synthesis of chiral 2-substituted piperazine and its derivatives | SHANGHAI INST MATERIA MEDICA (CN) | 2005-06-22 | — | — | CN | disclosed |
| US-20050090533-A1 | Dual NK1/NK3 receptor antagonists | F. HOFMANN-LA ROCHE AG (CH) | 2005-04-28 | — | — | US | disclosed |
| WO-2005002577-A1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |
| US-20040162282-A1 | Substituted piperazines | CHEMOCENTRYX, INC. | 2004-08-19 | — | — | US | disclosed |
| US-20040092507-A1 | Melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-05-13 | — | — | US | disclosed |
| EP-1368340-A1 | PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-12-10 | — | — | EP | disclosed |
| EP-1204654-B1 | BENZOFURYLPIPERAZINES: 5-HT2C SEROTONIN RECEPTOR AGONISTS | LILLY CO ELI (US) | 2003-07-23 | — | — | EP | disclosed |
| WO-2002059108-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092507-A1 | Melanocortin receptor agonists | MC1R, MC4R, MC5R | SIGMAR1 318/4885ACHE 3483/4885LTA4H 1589/4885 |
| US-20050090533-A1 | Dual NK1/NK3 receptor antagonists | TACR2, TAC3, TACR1 | SIGMAR1 336/4885ACHE 3263/4885LTA4H 1010/4885 |
| US-20240067625-A1 | SMALL-MOLECULE MODULATORS OF THE ORPHAN NUCLEAR RECEPTOR TLX | NR2E1, NR2E3, NR4A2 | SIGMAR1 812/4885ACHE 2535/4885LTA4H 823/4885 |
| US-20130210811-A1 | PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME | HSD11B1, HSD11B2, G6PC1 | SIGMAR1 3966/4885ACHE 3723/4885LTA4H 256/4885 |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | SMO, GLI1, SHH | SIGMAR1 3478/4885ACHE 2659/4885LTA4H 4017/4885 |
| US-20040162282-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | SIGMAR1 342/4885ACHE 4869/4885LTA4H 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.